MAPLE-HCM

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg)CompletedCompletedPhase 3Open NCT05767346 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…

MAPLE-HCM · Trial Tracker · ComplyRx